Literature DB >> 20390437

Prognostic value of pretreatment 18F-FDG PET in patients with primary central nervous system lymphoma: SUV-based assessment.

Nobuyuki Kawai1, Hai-Ning Zhen, Keisuke Miyake, Yuka Yamamaoto, Yoshihiro Nishiyama, Takashi Tamiya.   

Abstract

The purpose of this retrospective study was to evaluate the prognostic value of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in immunocompetent patients with primary central nervous system lymphoma (PCNSL). We also investigated whether FDG uptake was related to angiogenesis in the tumors. Seventeen patients with newly diagnosed and histologically confirmed PCNSL were investigated with FDG-PET before the treatment. FDG uptake was assessed by standardized uptake value of the tumor showing the maximum uptake (SUVmax). The Kaplan–Meier method was used to estimate the overall and the progression-free survival times. The difference of the survival curves between the low to moderate FDG uptake (SUVmax < 12) and high FDG uptake (SUVmax ≥ 12) groups was statistically analyzed. The relationship between FDG SUVmax and microvessel density (MVD) in the tumor specimens determined by CD34 immunohistochemical staining was examined. Finally, the difference of the overall survival curve between the low MVD (<20) and high MVD (≥ 20) groups was statistically analyzed. After the completion of initial treatment, 7 of the 8 low to moderate FDG uptake patients showed complete response (CR) and 1 showed partial response (PR). On the other hand, 5 of the 9 high FDG uptake patients showed CR and 4 showed PR. However, the difference of treatment response (CR vs PR) between the low to moderate and high FDG uptake groups was not statistically significant (P = 0.36). Median survival time was more than 26 months in low to moderate FDG uptake patients and 12 months in high FDG uptake patients. The overall survival time of patients with low to moderate FDG uptake was significantly longer than that of patients with high FDG uptake (P < 0.05). The progression free survival (PFS) was also significantly longer in patients with low to moderate FDG uptake compared to the patients with high FDG uptake (P < 0.05). There was no significant relationship between FDG SUVmax and MVD in the tumors. The survival time tended to be longer in patients with high MVD than in low MVD, but the difference was not statistically significant (P = 0.15). Pretreatment FDG uptake may have a prognostic value in newly diagnosed PCNSL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20390437     DOI: 10.1007/s11060-010-0182-0

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  35 in total

1.  PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.

Authors:  Lale Kostakoglu; Morton Coleman; John P Leonard; Ichiei Kuji; Holly Zoe; Stanley J Goldsmith
Journal:  J Nucl Med       Date:  2002-08       Impact factor: 10.057

2.  FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up.

Authors:  H Palmedo; H Urbach; H Bender; U Schlegel; I G H Schmidt-Wolf; A Matthies; M Linnebank; A Joe; J Bucerius; H-J Biersack; H Pels
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-12       Impact factor: 9.236

3.  Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis.

Authors:  Chieh Lin; Emmanuel Itti; Corinne Haioun; Yolande Petegnief; Alain Luciani; Jehan Dupuis; Gaetano Paone; Jean-Noël Talbot; Alain Rahmouni; Michel Meignan
Journal:  J Nucl Med       Date:  2007-09-14       Impact factor: 10.057

4.  Lung tumors evaluated with FDG-PET and dynamic CT: the relationship between vascular density and glucose metabolism.

Authors:  Ukihide Tateishi; Hiroshi Nishihara; Eriko Tsukamoto; Toshiaki Morikawa; Nagara Tamaki; Kazuo Miyasaka
Journal:  J Comput Assist Tomogr       Date:  2002 Mar-Apr       Impact factor: 1.826

5.  Angiogenesis in primary central nervous system lymphoma (PCNSL).

Authors:  Hiroaki Takeuchi; Ken Matsuda; Ryuhei Kitai; Kazufumi Sato; Toshihiko Kubota
Journal:  J Neurooncol       Date:  2007-04-04       Impact factor: 4.130

6.  Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma.

Authors:  Igor T Gavrilovic; Adília Hormigo; Joachim Yahalom; Lisa M DeAngelis; Lauren E Abrey
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

7.  Evaluation of tumor FDG transport and metabolism in primary central nervous system lymphoma using [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) kinetic analysis.

Authors:  Nobuyuki Kawai; Yoshihiro Nishiyama; Keisuke Miyake; Takashi Tamiya; Seigo Nagao
Journal:  Ann Nucl Med       Date:  2005-12       Impact factor: 2.668

8.  Primary central nervous system lymphoma in Japan: a nationwide survey.

Authors:  N Hayabuchi; Y Shibamoto; Y Onizuka
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-05-01       Impact factor: 7.038

9.  11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET.

Authors:  Sungeun Kim; June-Key Chung; So-Hyang Im; Jae Min Jeong; Dong Soo Lee; Dong Gyu Kim; Hee Won Jung; Myung Chul Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-08-10       Impact factor: 9.236

10.  Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience.

Authors:  Andrés J M Ferreri; Jean-Yves Blay; Michele Reni; Felice Pasini; Michele Spina; Achille Ambrosetti; Antonello Calderoni; Andrea Rossi; Vittorio Vavassori; Annarita Conconi; Liliana Devizzi; Françoise Berger; Maurilio Ponzoni; Bettina Borisch; Marianne Tinguely; Michele Cerati; Mario Milani; Enrico Orvieto; Juvenal Sanchez; Christine Chevreau; Stefania Dell'Oro; Emanuele Zucca; Franco Cavalli
Journal:  J Clin Oncol       Date:  2003-01-15       Impact factor: 44.544

View more
  14 in total

1.  18F-FDG PET/CT in primary brain lymphoma.

Authors:  Domenico Albano; Giovanni Bosio; Mattia Bertoli; Raffaele Giubbini; Francesco Bertagna
Journal:  J Neurooncol       Date:  2017-11-17       Impact factor: 4.130

2.  Flow-metabolism uncoupling in the cervical spinal cord of ALS patients.

Authors:  Toru Yamashita; Tetsuhiro Hatakeyama; Kota Sato; Yusuke Fukui; Nozomi Hishikawa; Yasuyuki Ohta; Yoshihiro Nishiyama; Nobuyuki Kawai; Takashi Tamiya; Koji Abe
Journal:  Neurol Sci       Date:  2017-01-24       Impact factor: 3.307

3.  Correlation between positron emission tomography findings and glucose transporter 1, 3 and L-type amino acid transporter 1 mRNA expression in primary central nervous system lymphomas.

Authors:  Yoshinobu Takahashi; Toshiaki Akahane; Daisuke Yamamoto; Hideo Nakamura; Hiroki Sawa; Kazumi Nitta; Wataru Ide; Ikuo Hashimoto; Hajime Kamada
Journal:  Mol Clin Oncol       Date:  2014-05-05

4.  Evaluating the Predictive Ability of Initial Staging F-18 FDG PET/CT for the Prognosis of Non-Hodgkin Malignant Lymphoma Patients Who Underwent Stem Cell Transplantation.

Authors:  Yun Soo Park; Seok Mo Lee; Ji Sun Park; Sang Kyun Bae; Hye-Kyung Shim; Won-Sik Lee; Sang-Min Lee
Journal:  Nucl Med Mol Imaging       Date:  2017-11-21

5.  Utility of FDG PET/CT in the Management of Primary Testicular Lymphoma.

Authors:  Kürşat Okuyucu; Semra İnce; Engin Alagöz; Erman Ataş; Nuri Arslan
Journal:  Mol Imaging Radionucl Ther       Date:  2018-06-07

6.  Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphoma-a narrative review.

Authors:  Simone Krebs; Julia G Barasch; Robert J Young; Christian Grommes; Heiko Schöder
Journal:  Ann Lymphoma       Date:  2021-06-30

7.  Imaging primary prostate cancer with 11C-Choline PET/CT: relation to tumour stage, Gleason score and biomarkers of biologic aggressiveness.

Authors:  Ji Chen; Yong Zhao; Xin Li; Peng Sun; Muwen Wang; Ridong Wang; Xunbo Jin
Journal:  Radiol Oncol       Date:  2012-06-19       Impact factor: 2.991

Review 8.  18F-FDG PET in the diagnosis and treatment of primary central nervous system lymphoma.

Authors:  Nobuyuki Kawai; Keisuke Miyake; Yuka Yamamoto; Yoshihiro Nishiyama; Takashi Tamiya
Journal:  Biomed Res Int       Date:  2013-06-17       Impact factor: 3.411

Review 9.  Primary CNS lymphoma.

Authors:  Elizabeth H Phillips; Christopher P Fox; Kate Cwynarski
Journal:  Curr Hematol Malig Rep       Date:  2014-09       Impact factor: 3.952

Review 10.  Diagnostic value of using 18F-FDG PET and PET/CT in immunocompetent patients with primary central nervous system lymphoma: A systematic review and meta-analysis.

Authors:  Yaru Zou; Jianjing Tong; Haiyan Leng; Jingwei Jiang; Meng Pan; Zi Chen
Journal:  Oncotarget       Date:  2017-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.